Chemistry:Foralumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD3 epsilon |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Foralumab is a fully human monoclonal antibody that binds to CD3 epsilon.[1] Also called TZLS-401, it is currently in clinical development by Tiziana Life Sciences for treatment of Crohn's disease and other autoimmune diseases.[2] However foralumab did not show efficacy for Crohn's disease.[3]
It is currently in clinical development by Tiziana Life Sciences for treatment of secondary progressive Multiple sclerosis.[4][5]
References
- ↑ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103". WHO Drug Information. https://www.who.int/medicines/publications/druginformation/INN_PL103.pdf.
- ↑ "Foralumab". Tiziana Life Sciences plc. http://www.tizianalifesciences.com/drug-pipeline/foralumab/.
- ↑ "Targeting T cells in inflammatory bowel disease". Pharmacological Research 159: 105040. September 2020. doi:10.1016/j.phrs.2020.105040. PMID 32585338.
- ↑ "2nd SPMS Patient Sees Clinical Gains With Foralumab Treatment". Multiple Sclerosis News Today. https://multiplesclerosisnewstoday.com/news-posts/2022/06/16/2nd-spms-patient-sees-clinical-gains-with-foralumab-treatment/.
- ↑ "Intranasal Foralumab Provides Neuroimaging and Clinical Improvements in Secondary Progressive Multiple Sclerosis". practicalneurology. https://practicalneurology.com/news/intranasal-foralumab-provides-neuroimaging-and-clinical-improvements-in-secondary-progressive-multiple-sclerosis.
 |  |
